H-CYTE, Inc. (OTCPK:HCYT) acquired Jantibody, LLC from Michael Yurkowsky and others on September 7, 2022. As for consideration, H-CYTE, Inc. exchanged 100% of the issued and outstanding membership interests in Jantibody, LLC for an aggregate of 52,023 shares at $0.001 par value per share. Michael Yurkowsky, the Chief Executive Officer of H-CYTE, Inc. directly held 25.77% membership interest in Jantibody and was its Managing Member. Pursuant to the transaction, Michael Yurkowsky received 13,406 shares of H-CYTE, Inc. common stock in exchange for his membership interests of Jantibody, LLC. In addition, Jantibody, LLC members will be entitled to receive additional shares of the H-CYTE, Inc. common stock upon the exercise or conversion of certain derivative securities of the Company which are outstanding on the date hereof, as well as upon the successful execution of certain milestones with respect to Jantibody's technology.

H-CYTE, Inc. (OTCPK:HCYT) completed the acquisition of Jantibody, LLC from Michael Yurkowsky and others for $1.9 million on September 7, 2022. The purchase price of approximately $247,000 represented 52,023 shares of the Company's common stock and 344,159 Anti-Dilution shares. The H-CYTE's board of directors approved the acquisition agreement. Prior to the acquisition, Michael Yurkowsky, CEO, had approximately 17.5 % ownership interest in Jantibody.